{"id":307013,"date":"2026-10-14T10:35:31","date_gmt":"2026-10-14T05:05:31","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=307013"},"modified":"2026-10-14T10:35:31","modified_gmt":"2026-10-14T05:05:31","slug":"solara-active-pharma-vs-hikal-vs-nectar-lifesciences","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/","title":{"rendered":"Solara Active Pharma vs Hikal vs Nectar Lifesciences: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Solara Active Pharma Sciences PE NA, mkt cap Rs 3,187 crore. Hikal PE NA, mkt cap Rs 2,629 crore. Nectar Lifesciences PE NA, mkt cap Rs 198 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences is a side-by-side comparison of three companies from the pharma and API manufacturing space. On this comparison, Solara Active Pharma Sciences carries a market capitalisation of about Rs 3,187 crore, against Rs 2,629 crore for Hikal and Rs 198 crore for Nectar Lifesciences, with return on equity of -0.12%, 3.03% and -9.85% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences starts with the core numbers most investors compare within the pharma and API manufacturing segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and API manufacturing bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=solara-active-pharma-vs-hikal-vs-nectar-lifesciences\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences_Company_Overview\" title=\"Solara Active Pharma Sciences, Hikal and Nectar Lifesciences: Company Overview\">Solara Active Pharma Sciences, Hikal and Nectar Lifesciences: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Valuation_and_Profitability_Snapshot\" title=\"Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Valuation and Profitability Snapshot\">Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Latest_Quarterly_Results\" title=\"Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Latest Quarterly Results\">Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Five-Quarter Revenue and Net Profit Trend\">Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#FAQs_on_Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences\" title=\"FAQs on Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences\">FAQs on Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#What_is_the_market_cap_difference_between_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\" title=\"What is the market cap difference between Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\">What is the market cap difference between Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#What_are_the_PE_and_PB_ratios_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\" title=\"What are the PE and PB ratios of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\">What are the PE and PB ratios of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#What_is_the_debt_to_equity_ratio_for_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\" title=\"What is the debt to equity ratio for Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\">What is the debt to equity ratio for Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\" title=\"What were the latest quarterly revenue and net profit of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\">What were the latest quarterly revenue and net profit of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences\/#Does_this_comparison_recommend_one_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\" title=\"Does this comparison recommend one of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\">Does this comparison recommend one of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences_Company_Overview\"><\/span><strong>Solara Active Pharma Sciences, Hikal and Nectar Lifesciences: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Solara Active Pharma Sciences<\/strong> is a listed Indian company in the pharma and API manufacturing space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 3,187 crore, a return on equity of -0.12% and a book value of Rs 258.98 per share. Its quarterly revenue moved from Rs 320.13 crore in June 2025 to Rs 384.29 crore in June 2026, a change of +20.0%.<\/p>\n<p><strong>Hikal<\/strong> is a listed Indian company in the pharma and API manufacturing space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,629 crore, a return on equity of 3.03% and a book value of Rs 97.22 per share. Its quarterly revenue moved from Rs 381.40 crore in June 2025 to Rs 404.60 crore in June 2026, a change of +6.1%.<\/p>\n<p><strong>Nectar Lifesciences<\/strong> is a listed Indian company in the pharma and API manufacturing space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 198 crore, a return on equity of -9.85% and a book value of Rs 29.97 per share. Its quarterly revenue moved from Rs 6.48 crore in June 2025 to Rs 3.36 crore in June 2026, a change of -48.1%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Valuation_and_Profitability_Snapshot\"><\/span><strong>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/solara\/solara-active-pharma-sciences-ltd-share-price-today\">Solara Active Pharma Sciences<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/hikal\/hikal-ltd-share-price-today\">Hikal<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/neclife\/nectar-lifesciences-ltd-share-price-today\">Nectar Lifesciences<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 3,187 crore<\/td>\n<td>Rs 2,629 crore<\/td>\n<td>Rs 198 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>NA<\/td>\n<td>NA<\/td>\n<td>NA<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.54<\/td>\n<td>2.19<\/td>\n<td>0.34<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>-0.12%<\/td>\n<td>3.03%<\/td>\n<td>-9.85%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>-0.33<\/td>\n<td>-2.74<\/td>\n<td>-12.61<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<td>0.28%<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.55<\/td>\n<td>0.57<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>258.98<\/td>\n<td>97.22<\/td>\n<td>29.97<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Solara Active Pharma Sciences trades at a PE of NA and a PB of 2.54, Hikal at a PE of NA and a PB of 2.19, while Nectar Lifesciences trades at a PE of NA and a PB of 0.34. On return on equity, the three post -0.12%, 3.03% and -9.85% respectively, and on dividend yield they stand at 0.00%, 0.28% and 0.00%. Solara Active Pharma Sciences has the highest market capitalisation of the three at Rs 3,187 crore, while Nectar Lifesciences has the lowest at Rs 198 crore. Hikal has the highest return on equity of the three at 3.03%, while Nectar Lifesciences has the lowest at -9.85%. Hikal has the highest debt to equity ratio of the three at 0.57, while Nectar Lifesciences has the lowest at 0.00. Debt to equity is 0.55, 0.57 and 0.00 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Latest_Quarterly_Results\"><\/span><strong>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Solara Active Pharma Sciences<\/td>\n<td>Rs 384.29 crore<\/td>\n<td>Rs 16.31 crore<\/td>\n<td>+20.0%<\/td>\n<td>-2.0%<\/td>\n<td>+55.0%<\/td>\n<\/tr>\n<tr>\n<td>Hikal<\/td>\n<td>Rs 404.60 crore<\/td>\n<td>-Rs 7.40 crore<\/td>\n<td>+6.1%<\/td>\n<td>-23.1%<\/td>\n<td>NA<\/td>\n<\/tr>\n<tr>\n<td>Nectar Lifesciences<\/td>\n<td>Rs 3.36 crore<\/td>\n<td>-Rs 15.40 crore<\/td>\n<td>-48.1%<\/td>\n<td>-55.7%<\/td>\n<td>NA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Solara Active Pharma Sciences<\/th>\n<th>Hikal<\/th>\n<th>Nectar Lifesciences<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 320.13 crore<\/td>\n<td>Rs 381.40 crore<\/td>\n<td>Rs 6.48 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 314.03 crore<\/td>\n<td>Rs 320.40 crore<\/td>\n<td>Rs 0.74 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 349.00 crore<\/td>\n<td>Rs 497.10 crore<\/td>\n<td>Rs 0.66 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 391.98 crore<\/td>\n<td>Rs 526.00 crore<\/td>\n<td>Rs 7.58 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 384.29 crore<\/td>\n<td>Rs 404.60 crore<\/td>\n<td>Rs 3.36 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Solara Active Pharma Sciences<\/th>\n<th>Hikal<\/th>\n<th>Nectar Lifesciences<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 10.52 crore<\/td>\n<td>-Rs 22.40 crore<\/td>\n<td>-Rs 63.23 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>-Rs 10.10 crore<\/td>\n<td>-Rs 34.90 crore<\/td>\n<td>-Rs 176.01 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>-Rs 17.43 crore<\/td>\n<td>-Rs 5.90 crore<\/td>\n<td>Rs 14.27 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 9.60 crore<\/td>\n<td>Rs 14.40 crore<\/td>\n<td>-Rs 67.92 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 16.31 crore<\/td>\n<td>-Rs 7.40 crore<\/td>\n<td>-Rs 15.40 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Solara Active Pharma Sciences reported revenue of Rs 320.13 crore in June 2025 and Rs 384.29 crore in June 2026, a change of +20.0% across the period. Its highest quarterly revenue in this window was Rs 391.98 crore in March 2026. Net profit stood at Rs 16.31 crore in June 2026, which is a net profit margin of 4.24%. Solara Active Pharma Sciences reported a net loss in September 2025 and December 2025.<\/p>\n<p>Hikal reported revenue of Rs 381.40 crore in June 2025 and Rs 404.60 crore in June 2026, a change of +6.1% across the period. Its highest quarterly revenue in this window was Rs 526.00 crore in March 2026. Net profit stood at -Rs 7.40 crore in June 2026, which is a net profit margin of -1.83% (a net loss for the quarter). Hikal reported a net loss in June 2025, September 2025, December 2025 and June 2026.<\/p>\n<p>Nectar Lifesciences reported revenue of Rs 6.48 crore in June 2025 and Rs 3.36 crore in June 2026, a change of -48.1% across the period. Its highest quarterly revenue in this window was Rs 7.58 crore in March 2026. Net profit stood at -Rs 15.40 crore in June 2026, which is a net profit margin of -458.33% (a net loss for the quarter). Nectar Lifesciences reported a net loss in June 2025, September 2025, March 2026 and June 2026.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Solara Active Pharma Sciences, Hikal and Nectar Lifesciences live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and API manufacturing names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory inspections, API pricing, customer concentration, raw material costs and debt levels. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences highlights how differently three companies in the same pharma and API manufacturing segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Solara_Active_Pharma_Sciences_vs_Hikal_vs_Nectar_Lifesciences\"><\/span><strong>FAQs on Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\"><\/span><strong>What is the market cap difference between Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Solara Active Pharma Sciences has a market cap of approximately Rs 3,187 crore, Hikal is at approximately Rs 2,629 crore, and Nectar Lifesciences is at approximately Rs 198 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\"><\/span><strong>What are the PE and PB ratios of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at NA, NA and NA respectively, and the price to book ratios stand at 2.54, 2.19 and 0.34 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Solara Active Pharma Sciences, Hikal and Nectar Lifesciences post ROE of -0.12%, 3.03% and -9.85% respectively as of October 2026. Hikal has the highest return on equity of the three at 3.03%, while Nectar Lifesciences has the lowest at -9.85%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Solara Active Pharma Sciences, Hikal and Nectar Lifesciences carry dividend yields of 0.00%, 0.28% and 0.00% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\"><\/span><strong>What is the debt to equity ratio for Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Solara Active Pharma Sciences carries a debt to equity of 0.55, Hikal of 0.57, and Nectar Lifesciences of 0.00.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\"><\/span><strong>What were the latest quarterly revenue and net profit of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Solara Active Pharma Sciences reported revenue of Rs 384.29 crore and net profit of Rs 16.31 crore, Hikal reported revenue of Rs 404.60 crore and net profit of -Rs 7.40 crore, and Nectar Lifesciences reported revenue of Rs 3.36 crore and net profit of -Rs 15.40 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Solara_Active_Pharma_Sciences_Hikal_and_Nectar_Lifesciences\"><\/span><strong>Does this comparison recommend one of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Solara Active Pharma Sciences has a market cap of approximately Rs 3,187 crore, Hikal is at approximately Rs 2,629 crore, and Nectar Lifesciences is at approximately Rs 198 crore.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at NA, NA and NA respectively, and the price to book ratios stand at 2.54, 2.19 and 0.34 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Solara Active Pharma Sciences, Hikal and Nectar Lifesciences post ROE of -0.12%, 3.03% and -9.85% respectively as of October 2026. Hikal has the highest return on equity of the three at 3.03%, while Nectar Lifesciences has the lowest at -9.85%.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Solara Active Pharma Sciences, Hikal and Nectar Lifesciences carry dividend yields of 0.00%, 0.28% and 0.00% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Solara Active Pharma Sciences carries a debt to equity of 0.55, Hikal of 0.57, and Nectar Lifesciences of 0.00.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Solara Active Pharma Sciences reported revenue of Rs 384.29 crore and net profit of Rs 16.31 crore, Hikal reported revenue of Rs 404.60 crore and net profit of -Rs 7.40 crore, and Nectar Lifesciences reported revenue of Rs 3.36 crore and net profit of -Rs 15.40 crore.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Solara Active Pharma Sciences, Hikal and Nectar Lifesciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026.<\/p>\n","protected":false},"author":28,"featured_media":307009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[11978,1019],"class_list":["post-307013","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-api-manufacturing","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["307009"],"rank_math_title":["Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences"],"rank_math_description":["Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026."],"rank_math_focus_keyword":["Solara Active Pharma Sciences vs Hikal vs Nectar Lifesciences"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/solara-active-pharma-vs-hikal-vs-nectar-lifesciences-which-stock-should-you.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/307013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=307013"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/307013\/revisions"}],"predecessor-version":[{"id":307014,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/307013\/revisions\/307014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/307009"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=307013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=307013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=307013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}